ABSTRACT
Background/Aim To test the chemoresistance of a multi-directional nebulizer (MDN) and to establish and implement a perioperative clinical safety concept for its clinical use to deliver pressurised intraperitoneal aerosol chemotherapy (MDN-PIPAC).
Study design Ex-vivo nebulization of cytostatic drugs with the MDN device to assess chemoresistance/toxicological risks. Establishment of a perioperative safety concept for the clinical administration of MDN-PIPAC by ex- and in-vivo porcine simulation studies. Unicentric case series of 30 MDN-PIPACs in 21 patients with peritoneal surface malignancies (PSM). Endpoints were intraoperative adverse events and perioperative complications (Clavien-Dindo).
Results Toxicological studies/risk assessment confirm the safety of administering PIPAC with the MDN. The horizontal nozzles must protrude at least 7 mm beyond the most distal end of the trocar tip and lateral tilting should be prevented by fixation of the device in a single-arm holder. A total of 21 patients (male/female ratio: 2:1) with a mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs for peritoneal surface malignancies of different origin. ECOG 0 and 1 were seen in five and 16 patients, respectively. Thirteen, seven, and one patient underwent one, two, and three MDN-PIPACs, respectively. Two patients received only one cycle of MDN-PIPAC because they were considered candidates for cytoreductive surgery and heated intraperitoneal chemotherapy. There were no intraoperative technical/medical problems observed. Four patients suffered from postoperative grade I complications.
Conclusions Compounds leached during chemotherapy nebulization with the MDN are toxicologically safe. MDN-PIPAC administrations are safe and the postoperative course is comparable to that of the conventional PIPAC nebulizer.
MINI ABSTRACT Toxicological analyses confirm that doxorubicin, cisplatin, and oxaliplatin nebulized with the MDN do not release leachables that pose a toxicological risk to patients. Through technical risk analysis and PIPAC simulations, a safety concept for the administration of MDN-PIPAC was established. No technical/medical intraoperative adverse events were observed. The perioperative course was comparable to that of the conventional axial single-direction nebulizer (SDN) PIPAC.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00033077
Funding Statement
The animal experiments, were funded by the Association Tourangelle de recherche en oncologie du val de Loire (AT-ROVL)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The approval of the Ethics Committee of the Medical Faculty of the University of Muenster and the Medical Association Westphalia-Lippe in Germany (file # 2021-360-f-s) was obtained. The study (file # 40583) was approved by the French Ministry of Higher Education and Research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The content of the revised version is largely identical to the first version. However, additional tests/experiments have been included in the revised version. Schlieren tests were carried out in co-operation with the Department of Building Physics at the University of Weimar, Germany. These experiments/results have been incorporated into the manuscript. In addition, minor changes were made to the layout, language and spelling.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- AET
- Analytical Evaluation Threshold (ISO 10993-18 (2020)
- BSA
- Body Surface Area calculated according to DuBois
- CE
- Conformité Européenne
- DGAV
- Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
- ECOG
- Eastern Cooperative Oncology Group
- FDA
- U.S. Food and Drug Administration
- GC-MS
- Gas Chromatography coupled with Mass Spectrometry
- HSGC-MS
- Head-space Gas Chromatography coupled with Mass Spectrometry
- IC
- Ion Chromatography
- ICP-OES
- Inductively Coupled Plasma Atomic Emission Spectrometry
- LC-MS
- Liquid phase chromatography□coupled to a Mass Spectrometer
- MDN
- Multi-Directional Nebulizer (QuattroJet™, REGER Medizintechnik GmbH, Villigendorf, Germany)
- PCI
- Peritoneal Carcinomatosis Index according to Sugarbaker
- PIPAC
- Pressurized IntraPeritoneal Aerosol Chemotherapy
- PSM
- Peritoneal Surface Malignancies
- RIPAC
- Rotational intraperitoneal aerosol chemotherapy
- SDN
- Single-direction nebulizer
